On the stock market since 2007, it operates in the world of money and finance. It has 687 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
For a bank, strength is measured by capital buffers and reserves — not cash minus debt.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
Over the last 3 years, sales grew about 12% a year on average.
Over the last 12 months, company executives reported 32 buys and 24 sells. Management buying with its own money is usually read as a good sign.
It pays out $0.10 per share each year — regular cash for whoever holds the stock.
The stock trades 15% above the average analyst price target.
On our five-subject report card, CARE sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: CARE is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.